Low-Dose GnRH Agonist Therapy for the Management of Endometriosis.
|
Accession number;99A0894031
|
| Title;Low-Dose GnRH Agonist Therapy for the Management of Endometriosis. |
| Author;
UEMURA T
(Yokohama City Univ. School Of Medicine, Yokohama, Jpn)
SHIRASU K
(Yokohama-minamikyosai Hospital, Yokohama, Jpn)
KATAGIRI N
(Yokohama-minamikyosai Hospital, Yokohama, Jpn)
ASUKAI K
(Yokohama-minamikyosai Hospital, Yokohama, Jpn)
SUZUKI T
(Saiseikai-yokohama Nanbu Hospital, Yokohama, Jpn)
SUZUKI N
(Saiseikai-yokohama Nanbu Hospital, Yokohama, Jpn)
OSADA H
(Yokohama Municipal Citizen's Hospital, Yokohama, Jpn)
MINAGUCHI H
(Yokohama City Univ. School Of Medicine, Yokohama, Jpn)
|
Journal Title;J Obstet Gynaecol Res
|
Journal Code:Y0696A
|
ISSN:1341-8076
|
|
VOL.25;NO.5;PAGE.295-301(1999)
|
| Figure&Table&Reference;FIG.5, TBL.1, REF.10 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Objective: In order to examine whether treatment with a GnRH agonist alone can maintain estrogen levels within the "estrogen window" that inhibits endometriosis without influencing bone-mineral density, we studied the effects of GnRH agonist therapy and changes in bone-mineral density. Methods: Buserelin acetate nasal spray was administered 3 times a day for 8 weeks (daily dose, 900 .MU.g) to 21 women with endometriosis. The drug was then given twice a day for 16 weeks (daily dose, 600 .MU.g). The total duration of treatment was 24 weeks. The bone-mineral density of the lumbar vertebrae was measured by dual-energy X-ray absorptiometry before treatment (baseline), at the end of treatment, and 24 weeks after the end of treatment, Results: The bone-mineral density of the lumbar vertebrae at the end of treatment was 2.44%.+-.0.46% (mean.+-.standard error) lower than the baseline value. The value at 24 weeks after the end of treatment was 1.10%.+-.0.64% lower than the baseline value. More than 80% of the patients had serum-estradiol levels of 45 pg/ml or less. During treatment, more than 90% of the patients had serum-estradiol levels of 60 pg/ml or less. Genital bleeding was inhibited in 90% of the patients. After 8 weeks of treatment, the clinical symptoms improved in 75% of the patients; such improvement persisted for the duration of the treatment. Conclusion: Decreasing the dose of GnRH agonist during treatment can minimize the loss of bone-mineral density without lessening the beneficial effects on endometriosis. This technique might be useful in the management of endometriosis. (author abst.) |
|
|
|
Related Articles;
|
|
|
